Amplia Therapeutics (Amplia Therapeutics) Long-Term Debt : $0.04 Mil (As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Amplia Therapeutics Long-Term Debt?

Amplia Therapeutics's Long-Term Debt for the quarter that ended in Sep. 2023 was $0.04 Mil.

Amplia Therapeutics's quarterly Long-Term Debt declined from Sep. 2022 ($0.09 Mil) to Mar. 2023 ($0.00 Mil) but then increased from Mar. 2023 ($0.00 Mil) to Sep. 2023 ($0.04 Mil).

Amplia Therapeutics's annual Long-Term Debt increased from Mar. 2021 ($0.00 Mil) to Mar. 2022 ($1.55 Mil) but then declined from Mar. 2022 ($1.55 Mil) to Mar. 2023 ($0.00 Mil).

Amplia Therapeutics Long-Term Debt Historical Data

The historical data trend for Amplia Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amplia Therapeutics Long-Term Debt Chart

Amplia Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Long-Term Debt

Get a 7-Day Free Trial

1.55

Amplia Therapeutics Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Long-Term Debt	Get a 7-Day Free Trial															-	1.55	0.09	-	0.04

Amplia Therapeutics (OTCPK:INNMF) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Amplia Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Amplia Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Amplia Therapeutics (Amplia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amplia Therapeutics Ltd (OTCPK:INNMF) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

ATX:Australia

Address

350 Queen Street, Level 17, Melbourne, VIC, AUS, 3000

Website

https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. Its molecule, AMP945 is a pure-play inhibitor, while the second molecule, AMP886, is a multi-action molecule that hits two other important cancer pathways - VEGFR3 and FLT3.

Amplia Therapeutics (Amplia Therapeutics) Headlines

From GuruFocus

FDA CLEARANCE OF AMPLIA'S IND FOR PANCREATIC CANCER TRIAL IN US

By PRNewswire • 01-18-2024

AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer

By PRNewswire PRNewswire • 05-29-2023

AACR OVARIAN CANCER CONFERENCE PRESENTATION

By PRNewswire • 10-09-2023